SEC Filing Summary: Zafgen, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on January 13, 2020, covering events occurring on January 9, 2020. The registrant is a Delaware corporation with its principal executive offices in Boston, Massachusetts, and its common stock trades on the NASDAQ Global Market under the symbol ZFGN.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance and investor communications rather than financial performance data.
Material Changes
- Nasdaq Compliance: The Company previously received notice on September 17, 2019, of non-compliance with Nasdaq's minimum bid price requirement.
- Regained Compliance: On January 9, 2020, Nasdaq notified the Company that it had regained compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days ending January 8, 2020.
Guidance, Outlook, and Management Commentary
Management indicated participation in upcoming investor meetings. A presentation used for these meetings is included as Exhibit 99.1. The filing explicitly states that the information in the presentation is furnished and not "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the current trading status and bid price of ZFGN on the NASDAQ Global Market.
- Review Exhibit 99.1 (Investor Presentation) for forward-looking statements, noting they are not legally "filed" under the Exchange Act.
- Confirm the Company's ongoing compliance with Nasdaq listing standards beyond the minimum bid price requirement.
- Check subsequent filings for any updates on the Company's financial position, as this 8-K contains no financial data.